Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Locoregional Recurrence|Hormone Receptor-positive Breast Cancer|HER2-negative Breast Cancer
Interventions: DRUG: Ribociclib|DRUG: Fulvestrant|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane
Sponsor: Oana Danciu
Collaborators: Novartis Pharmaceuticals